The abstract is read at the publisher; the summary is JClub's.
Barzolvolimab improved UAS7 from baseline to week 12 in antihistamine-refractory chronic spontaneous urticaria, with the largest mean change at 300 mg every 8 weeks (-13.41).
- Why it matters: Mast cells are implicated in CSU, but clinical evidence linking mast cell depletion to symptom improvement across dose regimens has been limited.
- What they did: In a phase 2 double-blind placebo-controlled trial, adults with UAS7 ≥ 16 were randomized to barzolvolimab 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks, or placebo, and UAS7 change to week 12 was measured.
- The result: All barzolvolimab doses significantly reduced UAS7 versus placebo (P = .0017, P < .0001, P < .0001), with complete response at 12 weeks in 22.9%, 51.1%, and 37.5% versus 6.4% on placebo, and adverse events were generally well tolerated.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.